How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

7,477 results for

Thyroid Stimulating Hormone

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Thyroid replacement therapy, thyroid stimulating hormone concentrations, and long term health outcomes in patients with hypothyroidism: longitudinal study. Full Text available with Trip Pro

Thyroid replacement therapy, thyroid stimulating hormone concentrations, and long term health outcomes in patients with hypothyroidism: longitudinal study. To explore whether thyroid stimulating hormone (TSH) concentration in patients with a diagnosis of hypothyroidism is associated with increased all cause mortality and a higher risk of cardiovascular disease and fractures.Retrospective cohort study.The Health Improvement Network (THIN), a database of electronic patient records from UK primary

2019 BMJ

2. Recurrence after low-dose radioiodine ablation and recombinant human thyroid-stimulating hormone for differentiated thyroid cancer (HiLo): long-term results of an open-label, non-inferiority randomised controlled trial Full Text available with Trip Pro

Recurrence after low-dose radioiodine ablation and recombinant human thyroid-stimulating hormone for differentiated thyroid cancer (HiLo): long-term results of an open-label, non-inferiority randomised controlled trial Two large randomised trials of patients with well-differentiated thyroid cancer reported in 2012 (HiLo and ESTIMABL1) found similar post-ablation success rates at 6-9 months between a low administered radioactive iodine (131I) dose (1·1 GBq) and the standard high dose (3·7 GBq (...) status 0-2, tumour stage T1-T3 with the possibility of lymph-node involvement but no distant metastasis and no microscopic residual disease, and one-stage or two-stage total thyroidectomy). Patients were randomly assigned (1:1:1:1) to 1·1 GBq or 3·7 GBq ablation, each prepared with either recombinant human thyroid-stimulating hormone (rhTSH) or thyroid hormone withdrawal. Patients were followed up at annual clinic visits. Recurrences were diagnosed at each hospital with a combination of established

2019 EvidenceUpdates

3. Current Thyroid-stimulating Hormone Immunoassays Recognize Macro- thyroid-stimulating Hormone Leading to Hyperthyrotropinemia in Females of Reproductive Age. (Abstract)

Current Thyroid-stimulating Hormone Immunoassays Recognize Macro- thyroid-stimulating Hormone Leading to Hyperthyrotropinemia in Females of Reproductive Age. Macro-thyrotropin (macro-TSH) is a high molecular weight form of TSH that leads to hyperthyrotropinemia. This study was undertaken to examine the prevalence and nature of macro-TSH in females of reproductive age.Blood samples were taken from 1794 female patients who visited the Hamada Obstetrics and Gynecology Hospital in Tokyo, Japan

2018 Thyroid

4. Therapeutic challenges in the application of serum thyroid stimulating hormone testing in the management of patients with hypothyroidism on replacement thyroid hormone therapy: a review. (Abstract)

Therapeutic challenges in the application of serum thyroid stimulating hormone testing in the management of patients with hypothyroidism on replacement thyroid hormone therapy: a review. Normalizing serum thyroid stimulating hormone (TSH) levels by lifelong treatment with levothyroxine (LT4) remains the primary goal of therapy for patients with hypothyroidism. The reference ranges for TSH are derived from populations with (supposedly) normal thyroid function. But, TSH results are affected (...) may have a personal "set point" for thyroid hormone levels that represents normal function for that individual, but which is outside the population reference range. The introduction of updated LT4 formulations, with better dosing accuracy and stability compared with older versions, should, in theory at least, provide better stability and accuracy of dosing over time. However, the new LT4 formulations are associated with manifold increases in the number of self-reported adverse events. Therefore

2019 Current medical research and opinion

5. Thyroid hormones treatment for subclinical hypothyroidism Full Text available with Trip Pro

Levothyroxine Interventions compared Recommendation Population Adults with subclinical hypothyroidism Does not apply to: May not apply to: Including: Women who are or trying to become pregnant Patients with no symptoms (diagnosed after screening) Patients with non-specific symptoms Patients with severe symptoms Patients with TSH above 20 mIU/L Young adults (such as <30 years) Elevated levels of thyroid stimulating hormone (TSH) Normal free T4 (thyroxine) levels We recommend against thyroid hormone therapy (...) hormones are increasingly prescribed, most probably due to SCH Subclinical hypothyroidism (SCH) is a biochemical state. The thyroid stimulating hormone (TSH) level is elevated, but the free T4 (thyroxine) level is normal. Some people may experience symptoms linked to the abnormality. Other data have suggested links to overt hypothyroidism and adverse outcomes such as increased risk of coronary heart disease. So it is reasonable to ask whether treatment with thyroid hormones might help symptoms, prevent

2019 BMJ Rapid Recommendations

6. Thyroid function reference values in healthy iodine-sufficient pregnant women and influence of thyroid nodules on thyroid-stimulating hormone and free thyroxine values. (Abstract)

Thyroid function reference values in healthy iodine-sufficient pregnant women and influence of thyroid nodules on thyroid-stimulating hormone and free thyroxine values. Thyroid function assessment in pregnancy requires specific reference intervals stratified by gestational age and according to each laboratory method. Thyroid nodules may influence thyroid function in pregnant women. The aims of this study were to define the reference values of thyrotropin (TSH) and free thyroxine (fT4 (...) ) in the three pregnancy trimesters in iodine-sufficient pregnant women, and to analyze the influence of thyroid nodules on thyroid function during pregnancy.This was a prospective, longitudinal study comprising 400 pregnant women with no history of thyroid disease and no medication influencing thyroid function. TSH, fT4, antithyroglobulin, and antithyroid peroxidase antibodies were measured each trimester by chemiluminescent immunoassays. Urinary iodine concentration was measured in the first trimester when

2019 Thyroid

7. Routine Prenatal Thyroid-Stimulating Hormone Testing: Evidence-Based Guidelines

Routine Prenatal Thyroid-Stimulating Hormone Testing: Evidence-Based Guidelines Routine Prenatal Thyroid-Stimulating Hormone Testing: Evidence-Based Guidelines | CADTH.ca Find the information you need Routine Prenatal Thyroid-Stimulating Hormone Testing: Evidence-Based Guidelines Routine Prenatal Thyroid-Stimulating Hormone Testing: Evidence-Based Guidelines Published on: November 14, 2016 Project Number: RB1038-000 Product Line: Research Type: Other Diagnostics Report Type: Summary (...) of Abstracts Result type: Report Question What are the evidence-based guidelines for routine screening of thyroid-stimulating hormone in prenatal women? Key Message Four evidence-based guidelines were identified regarding routine screening of thyroid-stimulating hormone in prenatal women. Tags fear, fetus, pregnancy, pregnancy trimesters, pregnant women, thyroid diseases, thyroid function tests, thyrotropin, laboratory tests, Prenatal, foetus, iodine test, thyrotrophin, pregnant women, thyroid stimulating

2016 Canadian Agency for Drugs and Technologies in Health - Rapid Review

8. Effects of thyroid stimulating hormone on peripheral thyroid hormone metabolism and serum lipids. (Abstract)

Effects of thyroid stimulating hormone on peripheral thyroid hormone metabolism and serum lipids. Subclinical hypothyroidism is associated with dyslipidemia and atherosclerosis. Whether these effects are in part mediated via direct effects of thyrotropin (TSH) on peripheral thyroid hormone (TH) metabolism and/or concentrations of serum lipids is not clear.This study examined whether TSH has direct effects on peripheral TH metabolism and serum lipids.Eighty-two patients with differentiated (...) thyroid cancer were retrospectively analyzed. All patients had undergone total thyroidectomy and 131I remnant ablation. During follow-up, two successive injections of recombinant human TSH (rhTSH) were administered to patients on a stable dose of levothyroxine. In all patients, TSH, thyroxine (T4), free T4 (fT4), triiodothyronine (T3), reverse T3 (rT3), total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, apolipoprotein B, lipoprotein(a), and triglyceride

2018 Thyroid

9. Divergent patterns of thyroid-stimulating hormone and other thyroidal parameter levels in relationship with the sex of healthy neonates and infants less than two years old: a longitudinal study. (Abstract)

Divergent patterns of thyroid-stimulating hormone and other thyroidal parameter levels in relationship with the sex of healthy neonates and infants less than two years old: a longitudinal study. Background: A longitudinal study was conducted in full-term healthy infants who were born between 2015 and 2017 in Athens, Greece, to elucidate the evolution of thyrotropin (TSH) and other thyroidal parameters according to sex, from their day of birth until two years old. Other thyroidal parameters (...) to sex, especially in the first months of life and until the first year. Furthermore, our results suggest new optimal ranges for thyroid hormone replacement for that specific period.

2019 Thyroid

10. Thyroid hormone treatment does not help adults with mildly abnormal thyroid tests

evidence that hormone treatment of subclinical hypothyroidism, gives no measurable benefit either. This may help inform practice, spare patients unnecessary treatment, and save NHS resources. Share your views on the research. Why was this study needed? Hypothyroidism is a condition where the thyroid gland doesn’t produce enough hormones, which can have various underlying causes. Hypothyroidism is characterised by low blood levels of free thyroxine (T4) and high levels of thyroid stimulating hormone (...) of free thyroxine (T4) and high levels of thyroid stimulating hormone (TSH), which is released from the pituitary gland to try and stimulate the thyroid. Subclinical hypothyroidism is diagnosed when there is a raised level of TSH, but normal levels of free T4. It’s thought to affect around 5-6% of adults and is more common in women and older people. To date, there has been little evidence to guide the management of subclinical hypothyroidism. Two large randomised controlled trials were recently

2019 NIHR Dissemination Centre

11. Recombinant Human Thyroid-Stimulating Hormone Versus Thyroid Hormone Withdrawal in 124I PET/CT–Based Dosimetry for 131I Therapy of Metastatic Differentiated Thyroid Cancer Full Text available with Trip Pro

Recombinant Human Thyroid-Stimulating Hormone Versus Thyroid Hormone Withdrawal in 124I PET/CT–Based Dosimetry for 131I Therapy of Metastatic Differentiated Thyroid Cancer Patients with metastatic differentiated thyroid cancer (DTC) may be prepared using either thyroid-stimulating hormone withdrawal (THW) or recombinant human thyroid-stimulating hormone (rhTSH) injections before 131I administration for treatment. The objective of this study was to compare the absorbed dose to the critical (...) patient, the absorbed dose per unit administered activity of 131I was higher in the THW study than in the rhTSH study. The ratio of the average tumor absorbed dose after stimulation by THW compared with stimulation by rhTSH injections was 3.9, 27, and 1.4 for patient 1, patient 2, and patient 3, respectively. The ratio of mean tumor to bone marrow absorbed dose per unit administered activity of 131I, after THW and rhTSH, was 232 and 62 (patient 1), 12 and 0.78 (patient 2), and 22 and 11 (patient 3

2017 Journal of Nuclear Medicine

12. Thyroid-Stimulating Hormone, Thyroid Hormones and Risk of Papillary Thyroid Cancer: A Nested Case-Control Study. Full Text available with Trip Pro

Thyroid-Stimulating Hormone, Thyroid Hormones and Risk of Papillary Thyroid Cancer: A Nested Case-Control Study. Background: The effects of thyroid-stimulating hormone (TSH) and thyroid hormones on the development of human papillary thyroid cancer (PTC) remain poorly understood.Methods: The study population consisted of 741 (341 women, 400 men) histologically confirmed PTC cases and 741 matched controls with prediagnostic serum samples stored in the Department of Defense Serum Repository (...) was observed among both men and women.Impact: These results could have significant clinical implications for physicians who are managing patients with abnormal thyroid functions and those with thyroidectomy. Cancer Epidemiol Biomarkers Prev; 26(8); 1209-18. ©2017 AACR.©2017 American Association for Cancer Research.

2017 Cancer Epidemiology & Biomarkers and Prevention

13. Aberrant thyroid-stimulating hormone receptor signaling increases VEGF-A and CXCL8 secretion of thyroid cancer cells, contributing to angiogenesis and tumor growth. Full Text available with Trip Pro

Aberrant thyroid-stimulating hormone receptor signaling increases VEGF-A and CXCL8 secretion of thyroid cancer cells, contributing to angiogenesis and tumor growth. Thyroid-stimulating hormone (TSH) suppression is widely used to treat well-differentiated thyroid cancer, whereas its role in poorly differentiated thyroid cancer (PDTC) is undetermined. Besides thyrocytes, TSH also binds to stromal cells, comprising tumor microenvironments. This study aimed to investigate the effects of TSH (...) on tumor microenvironments in PDTC.An ectopic tumor model using PDTC cells (BHP10-3SCp and FRO), which exhibit TSH/cAMP-independent cell growth, was treated with TSH. IHC was performed using tissue microarrays from 13 PDTCs.TSH treatment significantly enhanced tumor growth of PDTCs with increased vascularity but not that of breast cancer cells, suggesting this effect is unique to thyroid cancer cells, not stromal cells. TSH significantly upregulated VEGF-A and CXCL8 expressions in BHP10-3SCp cells via

2018 Clinical Cancer Research

14. Clinical Significance of Thyroid-Stimulating Hormone Receptor Gene Mutations and/or Sodium-Iodine Symporter Gene Overexpression in Indeterminate Thyroid Fine Needle Biopsies Full Text available with Trip Pro

Clinical Significance of Thyroid-Stimulating Hormone Receptor Gene Mutations and/or Sodium-Iodine Symporter Gene Overexpression in Indeterminate Thyroid Fine Needle Biopsies Objectives: To examine the prevalence of genetic alterations of thyroid-stimulating hormone receptor (TSHR) gene and sodium-iodine symporter (NIS) in a series of thyroid fine needle biopsy (FNB) specimens with indeterminate cytology, and to assess the correlation of the type of genetic changes with clinical features (...) and follow-up results in the target thyroid nodule. Methods: Between February 2015 and September 2017, 388 consecutive FNBs with indeterminate cytology were evaluated for TSHR mutations and NIS gene overexpression using ThyroSeqV.2 next-generation sequencing (NGS) panel. Medical records were reviewed for target nodules. Results: Among 388 indeterminate FNBs, TSHR mutations and/or NIS overexpression were detected in 25 (6.4%) nodules. Ten nodules (2.6%) harbored TSHR mutations only, 7 nodules (1.8%) over

2018 Frontiers in endocrinology

15. Are Thyroid Autoimmune Diseases Associated with Cardiometabolic Risks in a Population with Normal Thyroid-Stimulating Hormone? Full Text available with Trip Pro

Are Thyroid Autoimmune Diseases Associated with Cardiometabolic Risks in a Population with Normal Thyroid-Stimulating Hormone? The interrelation between thyroid autoimmunity and cardiovascular risks is complex and has not been confirmed. This study aimed at evaluating whether there exists a relationship between thyroid autoimmune diseases (AITDs) and cardiometabolic risks in a large population with normal thyroid-stimulating hormone (TSH) levels.The data was obtained from a cross-sectional (...) study (SPECT-China study). This study enrolled 9082 subjects (3948 males and 5134 females) above 18 years with normal TSH levels. AITD was defined according to the positivity of TPOAb and TgAb as well as thyroid ultrasonography (US) findings.After full adjustment, TPOAb and/or TgAb positivity (TPO/TgAb (+)) was significantly associated with higher BMI, waist circumference (WC), and HbA1c only in women (P = 0.004, 0.026 and 0.032, respectively), while both TPO/TgAb positivity and US positivity (TPO

2018 Mediators of inflammation

16. Thyroid Nodule Management: Thyroid-Stimulating Hormone, Ultrasound, and Cytological Classification System for Predicting Malignancy Full Text available with Trip Pro

Thyroid Nodule Management: Thyroid-Stimulating Hormone, Ultrasound, and Cytological Classification System for Predicting Malignancy Thyroid nodule (TN) is a common thyroid disorder globally, and the incidence has been increasing in recent decades. The objective of this study was to determine the contribution of thyroid-stimulating hormone (TSH), ultrasound (US), and cytological classification system for predicting malignancy among the surgically excised nodules.A retrospective analysis (...) was performed between January 2012 and December 2014, using data drawn from 1188 patients (15-90 years), who had 1433 TN and fine-needle aspiration in Prince Sultan Military Medical City, Saudi Arabia. After reviewing all the thyroid cytopathological slides and US reports, classification was done based on the Bethesda System for Reporting Thyroid Cytology and the Thyroid Imaging Reporting and Data System (TI-RADS).A total of 1188 patients' medical records were reviewed for this study, among them 311

2018 Cancer informatics

17. Expression of BANCR promotes papillary thyroid cancer by targeting thyroid stimulating hormone receptor Full Text available with Trip Pro

Expression of BANCR promotes papillary thyroid cancer by targeting thyroid stimulating hormone receptor Papillary thyroid carcinoma (PTC) is the most common form of non-medullary thyroid cancer, accounting for ~80% of all cases of thyroid cancer. The aim of the present study was to explore the role of BRAF-activated long noncoding RNA (BANCR) in the development of PTC. Using reverse transcription-quantitative polymerase chain reaction (RT-qPCR), the mRNA expression levels of BANCR, thyroid (...) -stimulating hormone receptor (TSHR) and cyclin D1 between PTC and benign control thyroid nodule tissue samples from 60 patients were determined. Using RT-qPCR and western blot analysis, the expression levels of TSHR and cyclin D1 mRNA and protein were determined in cells transfected with BANCR-small interfering (si)RNA. An MTT assay and flow cytometry were used to analyze the effect of BANCR knockdown on the proliferation and cell cycle distribution of IHH-4 PTC cells. The expression of BANCR, TSHR

2018 Oncology letters

18. Thyroid stimulating hormone suppression time on cardiac function of patients with differentiated thyroid carcinoma Full Text available with Trip Pro

Thyroid stimulating hormone suppression time on cardiac function of patients with differentiated thyroid carcinoma This study was to investigate the influence of thyroid stimulating hormone (TSH) suppression time on the cardiac function of differentiated thyroid carcinoma (DTC) patients.105 DTC patients were divided into strict TSH suppression group (model group, TSH ≤ 0.1 mU/L) and general TSH suppression group (control group, TSH > 0.1 mU/L). According to the suppression time, these two (...) ventricular EF, PFR and BPM in patients less than half a year were higher than those in 6 months to 1 year for control group.Thyroid stimulating hormone suppression can influence the cardiac function of patients and with the prolongation of suppression time, regardless of the level of TSH suppression, the possibility of cardiac function depression in patients will increase. TSH may lower the risk of cardiovascular disease in high-risk patients than those in TSH patients with moderate or low risk

2018 Cancer cell international Controlled trial quality: uncertain

19. The prognostic value of serum thyroid-stimulating hormone level post-lobectomy in low- and intermediate-risk papillary thyroid carcinoma. (Abstract)

The prognostic value of serum thyroid-stimulating hormone level post-lobectomy in low- and intermediate-risk papillary thyroid carcinoma. This study was undertaken to determine the optimal thyroid-stimulating hormone (TSH) value associated with structural recurrence in patients with low-risk or intermediate-risk papillary thyroid carcinoma (PTC) who underwent thyroid lobectomy.Patients with PTC (n = 1047) who received thyroid lobectomy and central compartment node dissection were included (...) in the study.Structural recurrence occurred in 42 of the patients (4.0%), and no patient died of PTC. Multivariate analysis showed a primary tumor size (with a cut-off of 0.85 cm) and serum TSH level measured 1 year after the initial surgery (cut-off 1.85 mU/L) independently predicted structural recurrence.TSH levels during the early postoperative period need to be monitored and maintained in the lower normal range even in patients with low- or intermediate-risk PTC undergoing thyroid lobectomy.© 2018 Wiley

2018 Journal of Surgical Oncology

20. Sex-specific genetic influence on thyroid-stimulating hormone and free thyroxine levels, and interactions between measurements: KNHANES 2013-2015. Full Text available with Trip Pro

Sex-specific genetic influence on thyroid-stimulating hormone and free thyroxine levels, and interactions between measurements: KNHANES 2013-2015. Although a wide range of genetic influences on thyroid-stimulating hormone (TSH) and free thyroxine (fT4) levels have been reported, sex differences in the genetic influences have not been well described.We assessed TSH and fT4 levels in 2,250 subjects without thyroid peroxidase antibody, with data obtained from the Korea National Health (...) than in males. In addition, female-specific pleiotropy between TSH and fT4 might be a clue that this stronger genetic influences in females would mainly affect thyroid function per se, rather than other TSH-related factors that do not primarily trigger the negative feedback loop between TSH and fT4.

2018 PLoS ONE

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>